“苗药第一股”翻车：贵州百灵四年造假6.5亿，昔日贵州首富被禁入市场十年

Core Viewpoint - Guizhou Bailing, once hailed as the "first stock of Miao medicine," has been exposed for financial fraud spanning four years, leading to a fine of 10 million yuan and a change in stock designation to "ST Bailing" [1][2]. Financial Fraud Details - From 2019 to 2021, Guizhou Bailing inflated profits by a total of 655 million yuan through improper accounting of sales expenses, with 2020's inflated profit accounting for 115.35% of the reported total profit for that year [2][4]. - In 2023, the company reversed its approach, overstating sales expenses by 459 million yuan, resulting in a net loss of 415 million yuan, marking the first annual loss since its listing [4][10]. - The fraudulent activities involved delaying the recognition of sales expenses, thereby artificially inflating profits, which misled investors regarding the company's financial health [2][4]. Management and Regulatory Actions - The actual controller and chairman, Jiang Wei, faces a fine of 5 million yuan and a 10-year ban from the securities market due to his knowledge of the fraudulent activities and failure to act [6][10]. - Other executives, including the general manager, were fined a total of 15.6 million yuan for their roles in the financial misconduct [1][10]. - The company's stock was suspended for one day and will be subject to risk warnings, with a new trading limit of 5% following its relisting [10]. Company Background - Jiang Wei, who transformed Guizhou Bailing from a struggling company to a market leader, saw his wealth peak at 16.5 billion yuan in 2017 before facing financial difficulties due to high stock pledges [6][9]. - The company went public in 2010, raising approximately 1.381 billion yuan, but has since faced significant challenges leading to its current situation [7][9].